Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 12/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 10/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.39 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.39 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.39 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serine SCHEMBL5011214 | 0.88 | SLC1A1 (0.48) | GRIK1GRIK2SLC1A1SLC7A5PTGS1 | |
| Serine SCHEMBL5138193 | 0.88 | SLC1A1 (0.48) | GRIK1GRIK2SLC1A1SLC7A5PTGS1 | |
| Serine SCHEMBL21464138 | 0.86 | GRIK1 (0.50) | GRIK1GRIK2SLC1A1SLC7A5PTGS1 | |
| Serine SCHEMBL3264996 | 0.86 | SLC1A1 (0.46) | GRIK1GRIK2SLC1A1SLC7A5PTGS1 | |
| Serine SCHEMBL28554351 | 0.86 | LMNA (0.48) | GRIK1GRIK2SLC1A1SLC7A5PTGS1 | |
| Serine SCHEMBL21988617 | 0.86 | LMNA (0.48) | GRIK1GRIK2SLC1A1SLC7A5PTGS1 | |
| Serine SCHEMBL27681309 | 0.85 | — | — | |
| Serine SCHEMBL4953051 | 0.85 | — | — | |
| Serine SCHEMBL4953052 | 0.85 | — | — | |
| (D)-Serine SCHEMBL27832613 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10150794-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2018-12-11 | — | — | US | disclosed |
| WO-2018112078-A1 | GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR OPROZOMIB AND PROCESS TO MAKE THEREOF | AMGEN INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180161279-A1 | GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR OPROZOMIB AND PROCESS TO MAKE THEREOF | AMGEN INC. | 2018-06-14 | — | — | US | disclosed |
| WO-2018057453-A1 | IMMEDIATE RELEASE FORMULATIONS FOR OPROZOMIB | AMGEN INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20180078532-A1 | IMMEDIATE RELEASE FORMULATIONS FOR OPROZOMIB | AMGEN INC. (US) | 2018-03-22 | — | — | US | disclosed |
| US-20170260230-A1 | COMPUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2017-09-14 | — | — | US | disclosed |
| EP-2623113-B1 | Compound for enzyme inhibition | ONYX THERAPEUTICS INC (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2813241-B1 | Crystalline tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS INC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-9403868-B2 | Crystalline tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160213610-A1 | MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB | ONYX THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20120077855-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2012-03-29 | — | — | US | disclosed |
| EP-2408758-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | Onyx Therapeutics, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20100240903-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010108172-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| US-7687456-B2 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090203698-A1 | Compounds for Enzyme Inhibition | PROTEOLIX, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008140782-A2 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| EP-1948678-A1 | COMPOUNDS FOR ENZYME INHIBITION | Proteolix, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007056464-A1 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180078532-A1 | IMMEDIATE RELEASE FORMULATIONS FOR OPROZOMIB | OPRL1, OPRK1, OPRM1 | GRIK1 1830/4885GRIK2 1847/4885SLC1A1 783/4885 |
| US-20160213610-A1 | MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB | OPRL1, OPRM1, OPRK1 | GRIK1 1760/4885GRIK2 1795/4885SLC1A1 690/4885 |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, PSMB1, PSMB3 | GRIK1 4307/4885GRIK2 4392/4885SLC1A1 4318/4885 |
| US-20170260230-A1 | COMPUNDS FOR ENZYME INHIBITION | ANPEP, PSMB1, CPN1 | GRIK1 4050/4885GRIK2 3915/4885SLC1A1 3356/4885 |
| US-20180161279-A1 | GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR OPROZOMIB AND PROCESS TO MAKE THEREOF | GIPR, OPRL1, MLNR | GRIK1 467/4885GRIK2 487/4885SLC1A1 916/4885 |
| US-10150794-B2 | Compounds for enzyme inhibition | ANPEP, HPN, DNPEP | GRIK1 3819/4885GRIK2 3731/4885SLC1A1 3694/4885 |
| US-20090203698-A1 | Compounds for Enzyme Inhibition | ANPEP, HPN, DNPEP | GRIK1 3819/4885GRIK2 3731/4885SLC1A1 3694/4885 |
| US-20100240903-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTSC, PEPD | GRIK1 1543/4885GRIK2 2522/4885SLC1A1 3615/4885 |
| US-20120077855-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | CTSC, PEPD, PREP | GRIK1 1528/4885GRIK2 2542/4885SLC1A1 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.